Modelling COVID-19 vaccine breakthrough infections in highly vaccinated Israel—The effects of waning immunity and third vaccination dose

  1. Anyin Feng
  2. Uri Obolski
  3. Lewi Stone
  4. Daihai He

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

In August 2021, a major wave of the SARS-CoV-2 Delta variant erupted in the highly vaccinated population of Israel. The transmission advantage of the Delta variant enabled it to replace the Alpha variant in approximately two months. The outbreak led to an unexpectedly large proportion of breakthrough infections (BTI)–a phenomenon that received worldwide attention. Most of the Israeli population, especially those aged 60+, received their second dose of the vaccination four months before the invasion of the Delta variant. Hence, either the vaccine induced immunity dropped significantly or the Delta variant possesses immunity escaping abilities, or both. In this work, we model data obtained from the Israeli Ministry of Health, to help understand the epidemiological factors involved in the outbreak. We propose a mathematical model that captures a multitude of factors, including age structure, the time varying vaccine efficacy, time varying transmission rate, BTIs, reduced susceptibility and infectivity of vaccinated individuals, protection duration of the vaccine induced immunity, and the vaccine distribution. We fitted our model to COVID-19 cases among the vaccinated and unvaccinated, for <60 and 60+ age groups, and quantified the transmission rate, the vaccine efficacy over time and the impact of the third dose booster vaccine. The peak transmission rate of the Delta variant was found to be 2.14 times higher than that of the Alpha variant. The two-dose vaccine efficacy against infection dropped significantly from >90% to ~40% over 6 months. We further performed model simulations and quantified counterfactual scenarios examining what would happen if the booster had not been rolled out. We estimated that approximately 4.03 million infective cases (95%CI 3.19, 4.86) were prevented by vaccination overall, and 1.22 million infective cases (95%CI 0.89, 1.62) averted by the booster.

Article activity feed

  1. Version published to 10.1371/journal.pgph.0001211
  2. ScreenIT

    SciScore for 10.1101/2022.01.08.22268950: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    NIH rigor criteria are not applicable to paper type.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • No funding statement was detected.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2022.01.08.22268950v1 on medRxiv